PAREXEL and Osaka International Cancer Institute Form Alliance

PAREXEL International Corporation, global biopharma services provider, and Osaka International Cancer Institute announced that they have formed a partnership to advance clinical development in Japan. Together, they  aim to drive efficiencies in support of patient recruitment for clinical trials in oncology and hematology, and to develop new cancer treatments for patients.

Read the full release here.